Omnicell (OMCL) Stock Price, News & Analysis

Company Overview

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Key Stats

• Today's Range: $30.93 to $31.88
• 50-Day Range: $26.88 to $31.68
• 52-Week Range: $22.66 to $55.74
• Volume: 326,709 shs
• Average Volume: 566,992 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: 63.10
• Dividend Yield: N/A
• Price Target: $46.71
• Consensus Rating: Moderate Buy

Omnicell Stock Analysis - MarketRank™

Omnicell scored higher than 70% of companies evaluated by MarketBeat, and ranked 626th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Omnicell has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.76%

Earnings Growth

Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omnicell is 63.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omnicell is 63.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.97.

Price to Earnings Growth Ratio

Omnicell has a PEG Ratio of 9.00. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Omnicell has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.16% of the outstanding shares of Omnicell have been sold short.

Short Interest Ratio / Days to Cover

Omnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omnicell does not currently pay a dividend.

Dividend Growth

Omnicell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.16% of the outstanding shares of Omnicell have been sold short.

Short Interest Ratio / Days to Cover

Omnicell has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Omnicell has recently decreased by 11.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.22

News Sentiment

Omnicell has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Omnicell this week, compared to 6 articles on an average week.

Search Interest

1 people have searched for OMCL on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Omnicell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omnicell insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.52% of the stock of Omnicell is held by insiders.

Percentage Held by Institutions

97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMCL Stock Analysis - Frequently Asked Questions

How have OMCL shares performed this year?

Omnicell's stock was trading at $44.52 at the beginning of the year. Since then, OMCL stock has decreased by 29.0% and is now trading at $31.5950.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Thursday, July, 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. The business's revenue was up 5.0% on a year-over-year basis.
Read the conference call transcript.

Does Omnicell have any subsidiaries?

Omnicell subsidiaries include these companies: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others.

Who are Omnicell's major shareholders?

Top institutional shareholders of Omnicell include Sumitomo Mitsui Trust Group Inc. (3.04%), Geode Capital Management LLC (2.55%), Connor Clark & Lunn Investment Management Ltd. (0.99%) and Bank of New York Mellon Corp (0.65%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon.
View institutional ownership trends.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 8/12/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:OMCL
• CIK: 926326
• Web: www.omnicell.com
• Phone: (877) 415-9990
• Fax: 847-596-3402
• Employees: 3,670
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Omnicell: $46.71
• High Price Target: $64.00
• Low Price Target: $34.00
• Potential Upside/Downside: +51.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.50
• Trailing P/E Ratio: 61.66
• Forward P/E Ratio: 28.28
• P/E Growth: 9
• Net Income: $12.53 million
• Net Margins: 2.01%
• Pretax Margin: 3.14%
• Return on Equity: 4.27%
• Return on Assets: 2.44%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.42
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: $1.11 billion
• Price / Sales: 1.27
• Cash Flow: $3.06 per share
• Price / Cash Flow: 10.07
• Book Value: $26.84 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 45,930,000
• Free Float: 44,776,000
• Market Cap: $1.42 billion
• Optionable: Optionable
• Beta: 0.78